Metformin effects to carbohydrate and lipids metabolism in impaired glucose tolerance patients.
Abstract
16 patients with IGT were studied. Age of participant was 55.1?8.2 yrs. All patients was divide into two groups: treatment group (bagomet1700 a day and diet) and control group (only diet). Effect of therapy was access in HbA1c, fasting glucose (FG), HOMA, lipids, liver glucose production(LGP) and leptin, which investigate in intravenous glucose tolerance test (IVGTT).
Results.
Normalization of carbohydrate metabolism was discover in 37.5% in treatment group and in 12.5% in control group. HbA1c was decreasefrom 6.4 to 5.9 % (р<0.05), LGP was decrease from 4.6?1.3 mmol/l to 3.0 ?1.7 mmol/l and HOMA also was decrease in treatment group. We foundout significant decrease low-density lipoprotein and triglyceride levels in treatment group. We didnt find a change leptin level in treatment group.
Conclusion.
The therapy of bagomet leads to normalization of carbohydrate metabolism in 37.5% persons with IGT.
About the Authors
Alexander Vasil'evich Dreval'Inna Vladimirovna Misnikova
Irina Vladimirovna Trigolosova
Raisa Stepanovna Tishenina
References
1. Tuomilehto J., Lindstrom J., Eriksson J.D., Valle T.T., Hamalainen H., Ilanne-Parikka P. et al. Finnish Diabetes Prevention Study Group. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance //N. Engl. J. Med. 2001; 344 (18): Р. 1343-1350.
2. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., lachin J.M. et al. Diabetes Prevention Program Research Group. Reduction in incidence of Type 2 diabetes with lifestyle intervention or metformin. // N. Engl. J. Med. 2002; 346(6): P. 393-403.
3. The DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria // Arch. Intern. Med. 2001 161: P. 397-405.
4. Standards of Medical Care in Diabetes-2009 American Diabetes Association // Diabetes Care, 2009; 32.
5. Древаль А.В. Идентификация параметров одночастевых моделей внутривенного теста толерантности к глюкозе (обзор литературы) // «Лабораторное дело», № 1, 1988, С. 3-8.
6. Древаль А.В. Двумерный параметр кинетики глюкозы в диагностике сахарного диабета // «Лабораторное дело», № 4, 1988, С. 47-54.
7. Definition, diagnosis and classification of Diabetes Mellitus and its complications. - Geneva, W.H.O., 1999.
8. Sandhofer A., Laimer M., Ebenbichler C.F., Kaser S., Paulweber B., Patsch J.R. Soluble leptin receptor and soluble receptor-bound fraction of leptin in the metabolic syndrome // Obes. Res. 2003;11: Р. 760-768.
9. Ostlund R.E.-Jr., Wang J.W., Klein S., Gingerich R. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates // J. Clin. Endocrinol. Metab. 1996; 81: Р. 3909-3913.
10. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., Ohannesian J.P., Marco C.C., McKee L.J., Bauer T.L. Serum immunoreactive-leptin concentrations in normal-weight and obese humans // N. Engl. J. Med. 1996; 334: Р. 292-295.
11. Maffei M., Halaas J., Ravussin E., Pratley R.E., Lee G.H., Zhang Y., Fei H., Kim S., Lallone R., Ranganathan S. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects // Nat. Med. 1995;1: Р. 1155-1161.
12. Wu M.S., Jonston P., Sheu W.H., et al. Effect metformin on carbohydrate and lipoprotein metabolism in NIDDM patients // Diabetes care, 1990; 20;1: P. 1-8.
13. Qiao Q., Lindstrom J., Valle T. and Tuomilehto J. Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glucamia Diabet Med. 2003; 20: Р. 1027-1033.
14. Anderwald C., Muller G., Koca G., et al. Short-term leptin-dependent inhibition of hepatic gluconeogenesis is mediated by insulin receptorsubstrate- 2 // Mol. Endocrinol. 2002; 16: Р. 1612-1628.
15. Sivitz W.I., Walsh S.A., Morgen D.A. et al. Effects of leptin on insulin sensitivity in normal rats // Endocrinology. 138: P. 3395-3401, 1997.
16. Unger R. Lipotoxic Diseases // Annu. Rev. Med. 2002; 53: 319-3U6.
17. Klein J., Westphal S., Kraus D., et al. Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes // Journal of Endocrinology 2004 183: P. 299-307.
18. Paolisso G., Amato L., Eccellente R., et al. Effect of metformin on food intake in obese subjects // Eur. J. Clin. Invest. 1998. Jun;28(6): Р. 441-446.
19. Адрес в сети интернет: www.diabet.ru/ivgtt/ivgtt_en.htm.
Review
For citations:
Dreval' A.V., Misnikova I.V., Trigolosova I.V., Tishenina R.S. Metformin effects to carbohydrate and lipids metabolism in impaired glucose tolerance patients. Diabetes mellitus. 2010;13(2):63-67. (In Russ.)